CCR5 ameliorates Japanese encephalitis via dictating the ...
Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy
-
Upload
mahesh-shahi -
Category
Health & Medicine
-
view
21 -
download
1
Transcript of Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy
![Page 1: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/1.jpg)
Presented By; Mahesh Shahi
3rd semesterBachelor in
Pharmaceutical sciences,CCT
Emerging “CCR5 ANTAGONISTS”
Promising HIV Therapeutic Strategy
t
Tuesday, May 2, 2023Tuesday, May 2, 2023
![Page 2: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/2.jpg)
Saturday, May 07, 2016 Pharmaceutical seminar~ 2nd
Contents1. Quick review about HIV/AIDS2. Treatment3. Introduction 4. Chemistry5. Mechanism of action of Maraviroc6. Pharmacokinetics7. Indications8. Contraindications9. Side effects10. Drug Interactions11. Doses12. Precautions13. Dosage forms14. Storage15. Conclusion
12
![Page 3: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/3.jpg)
Tuesday, May 2, 2023
Quick Review of the HIV/AIDs
2
INTRODUCTION HISTORY
TRANMISSION SYMPTOMS
TREATMENT3
Pharmaceutical seminar~ 2nd
![Page 4: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/4.jpg)
Tuesday, May 2, 2023
3
CCR5 ANTAGONISTS
4
APLAVIROC
VICRIVIROC
MARAVIR
OC
Contd…
DRUGS
Pharmaceutical seminar~ 2nd
![Page 5: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/5.jpg)
Tuesday, May 2, 2023
4
TREAMENT
5
CCR5 ANTAGONISTS
CONCEPT
DISCOVE
RY
Pharmaceutical seminar~ 2nd
![Page 6: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/6.jpg)
Tuesday, May 2, 2023
5
INTRODUCTION
6
As CCR5 ANTAGONISTFDA approved – Auguest 6, 2007
Combination with HAART
Labeled – only in CCR5 Tropic
Selzentry - USACelsentric – Europe, Sep. 2007
Pharmaceutical seminar~ 2nd
![Page 7: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/7.jpg)
Tuesday, May 2, 2023
6
CHEMISTRY Formula = C29H41F2N5O
Molecular mass = 513.666 g/mol
IUPAC name = 4,4-difluoro-N-{(1S)-3-[3-(3-isopropyl- 5-methyl-
4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-
phenylpropyl}cyclohexanecarboxamide
7Pharmaceutical seminar~ 2nd
![Page 8: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/8.jpg)
Tuesday, May 2, 2023 Pharmaceutical seminar~ 2nd
7
INDICATION
8
Blocking the HIV virus from entering
Lowers the HIV complications
Decrease the risk of spreading
![Page 9: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/9.jpg)
Tuesday, May 2, 2023 Pharmaceutical seminar~ 2nd
8
Life cycle of HIV virus inside Host
![Page 10: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/10.jpg)
MECHANISM OF ACTION
Tuesday, May 2, 2023 Pharmaceutical seminar~ 2nd
9
![Page 11: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/11.jpg)
Tuesday, May 2, 2023
10
PHARMACOKINECTICSBioavailability First-pass metabolism systemic availability 23% Protein binding ~ 76%Metabolism Hepatic Biological Life 0.5 to 4 hours Excretion Rectal/Renal Half-Life Elimination 14 – 18 hours
11Pharmaceutical seminar~ 2nd
![Page 12: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/12.jpg)
Tuesday, May 2, 2023
11
DOSE CATEGORY AGE GROUP DOSE
Younger below 18 year
Not Available
Adult Above 18 year
Available
Geriatric Above 65 year Not Available
12
Note: Use: In combination with other antiretroviral agents, for patients infected with only CCR5-tropic HIV-1.Pharmaceutical seminar~ 2nd
![Page 13: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/13.jpg)
Tuesday, May 2, 2023
12
DOSE IN DETAIL With Potent CYP450 3A Inhibitors(e.g Nefazodone,
Clarithromycin)
150 mg orally twice a day With Other Concomitant Medications (e.g Nevirapine,
Raltegravir, all NRTIs etc
300 mg orally twice a day With potent CYP450 3A Inducers (e.g Carbamazepine,
Phenobarbital)
600 mg orally twice a day13
Pharmaceutical seminar~ 2nd
![Page 14: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/14.jpg)
Tuesday, May 2, 2023
13
SIDE EFFECTS1. Less CommonDifficulty having a bowel movement (stool) Difficulty with moving Increased or decreased appetite2. More CommonStomach discomfort or upset Loss of interest or pleasure Unusual tiredness
3. RareConvulsionVomiting of blood
Loss of voice Difficulty with breathing
14Pharmaceutical seminar~ 2nd
![Page 15: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/15.jpg)
Tuesday, May 2, 202314
CONTRAINDICATION
15
Hepatic impairment
Renal impairment
Cardiovascular disease
Pharmaceutical seminar~ 2nd
![Page 16: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/16.jpg)
Tuesday, May 2, 2023
15
DRUG INTERACTION Clarithromycin
Increase Plasma Concentration
Ketoconazole
Increase Plasma Concentration
Carbamazepine
Decrease Plasma Concentration
16Pharmaceutical seminar~ 2nd
![Page 17: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/17.jpg)
Tuesday, May 2, 2023
16
PRECAUTIONS Kidney problems
Liver problems
Alcohol
Low Blood Pressure
Hypersentivity
17Pharmaceutical seminar~ 2nd
![Page 18: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/18.jpg)
Tuesday, May 2, 2023
17
DOSAGE FORMS Tab. : 150,300 & 600 mg
18Pharmaceutical seminar~ 2nd
![Page 19: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/19.jpg)
Tuesday, May 2, 2023
18
STORAGE Tab.
Room temp. – below 15 - 30 c Protect from Sunlight and Moisture
19Pharmaceutical seminar~ 2nd
![Page 20: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/20.jpg)
Tuesday, May 2, 2023
19
CONCLUSIONPrevention is better
than cure !!! –no way…
20Pharmaceutical seminar~ 2nd
![Page 21: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/21.jpg)
Tuesday, May 2, 2023
20
REFERENCES Tripathi KD (2008) Essential Medical Pharmacology (6th Ed.), Jaypee Brothers
Publishers Private Limited, New Delhi, India, pp (770-776).
Katzung BG (2007) Basic and Clinical Pharmcology (10th Ed.), McGraw-Hill Medical,
New York, USA, pp (798-811).
URL 1: https://en.wikipedia.org/wiki/Maraviroc (Assessed on: April 28, 2016).
URL 2: http://www.drugs.com/mtm/maraviroc.html (Assessed on: May 4, 2016).
URL 3: http://www.medscape.com/hiv (Assessed on: May 4, 2016).
URL 4 : https://retrovirology.biomedcentral.com/articles/10.1186/1742-4690-10-43
(Assessed on: May 8, 2016).
21Pharmaceutical seminar~ 2nd
![Page 22: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/22.jpg)
Tuesday, May 2, 2023
21
Presented by;MAHESH SHAHI 22
Pharmaceutical seminar~ 2nd
![Page 23: Emerging “CCR5 ANTAGONISTS” Promising HIV Therapeutic Strategy](https://reader036.fdocuments.in/reader036/viewer/2022070521/58f073171a28ab0c5c8b45f1/html5/thumbnails/23.jpg)
Tuesday, May 2, 2023
2223
Pharmaceutical seminar~ 2nd